Trials / Completed
CompletedNCT00600249
Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.
Phase II Pilot Study Evaluating the Neoadjuvant Combination "Taxotere (Docetaxel) and Erbitux (Cetuximab) in Operable and "Triple Negative" Breast Cancer Patients. TENEO Study.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Centre Jean Perrin · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination "Taxotere-Erbitux".
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cetuximab | dosage : 5mg/ml one administration per week: 400 mg/m2 then 250 mg/m2 during 18 weeks |
| DRUG | Docetaxel | 100mg/m2 every 21 days 6 cycles of 21 days |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2012-05-01
- Completion
- 2012-05-01
- First posted
- 2008-01-24
- Last updated
- 2014-03-20
Locations
6 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00600249. Inclusion in this directory is not an endorsement.